Main Research Focus
Dr. Doebele’s research is focused on basic and translational research related to lung cancer. His laboratory is developing predictive biomarkers for targeted lung cancer therapy and studying the molecular mechanisms of resistance to targeted therapy in lung cancer. Dr. Doebele’s laboratory uses in vitro and in vivo models of lung cancer to understand the interplay of cell signaling networks that drive the growth and metastasis of lung tumors. His laboratory also evaluates blood and tumor samples from patients to identify genetic or protein markers of sensitivity and resistance to targeted therapies. Ultimately, these efforts will enable improvements in personalized therapy for lung cancer patients.
Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, Bunn PA, Barón AE, Franklin WA, Aisner DL, Varella-Garcia M, and Camidge DR. Oncogene Status Predicts Patterns of Metastatic Spread in Treatment-Naïve Non-Small Cell Lung Cancer. Cancer, In press.
Bunn, P.A. and Doebele, R.C. Genetic Testing for Lung Cancer: Reflex vs. Clinical Selection. J Clin Oncol 2011 29(15):1943-5. PMID: 21483017.
Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, Hercule P, , Helfrich BA, Doebele RC, Heasley LE. (2010) Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression. PLoS ONE 5(11): e14117. doi:10.1371/journal.pone.0014117
Camidge, D.R., Kono, S.A., Lu,X., Okuyama, S., Barón, A.E., Oton, A.B., Davies, A.M.,Varella-garcia,M., Franklin, W.A., and Doebele, R.C. Anaplastic Lymphoma Kinase (ALK) gene rearrangements in non-small cell lung cancer are associated with prolonged progression free survival on pemetrexed. J Thorac Oncol 2011; 6: 774-80.